Loss-of-function mutations in SLC30A8 protect against type 2 diabetes

Loss-of-function mutations protective against human disease provide in vivo validation of therapeutic targets, but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of ∼150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating varia...

Full description

Bibliographic Details
Main Authors:	Flannick, J, Thorleifsson, G, Beer, N, Jacobs, S, Grarup, N, Burtt, N, Mahajan, A, Fuchsberger, C, Atzmon, G, Benediktsson, R, Blangero, J, Bowden, D, Brandslund, I, Brosnan, J, Burslem, F, Chambers, J, Cho, Y, Christensen, C, Douglas, D, Duggirala, R, Dymek, Z, Farjoun, Y, Fennell, T, Fontanillas, P, Forsén, T
Format:	Journal article
Language:	English
Published:	Nature Publishing Group 2014

Loss-of-function mutations in SLC30A8 protect against type 2 diabetes

Similar Items